HER2 testing and its predictive utility in anti-HER2 breast cancer therapy-Reference-Cited by-同舟云学术

HER2 testing and its predictive utility in anti-HER2 breast cancer therapy

Published:2015-01 Issue:1 Volume:9 Page:35-49
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Advani Pooja P¹,Crozier Jennifer A¹,Perez Edith A¹²

Affiliation:

1. Division of Hematology & Oncology, Mayo Clinic, 4500 San Pablo Road S., Jacksonville, FL 32224, USA

2. Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road S., Jacksonville, FL 32224, USA

Abstract

Breast cancer treatment is dependent on accurate pathologic diagnosis. HER2 testing is now universally recommended as part of evaluation of invasive breast cancer. HER2 testing is available via various slide and non-slide based assays, and interpretation of results continues to evolve. Herein we review these testing modalities and their incorporation into the 2013 ASCO/CAP guidelines. Once accurate HER2 status has been established the proper treatment based on recent clinical trials can be instituted.

Publisher

Future Medicine Ltd

Subject

Biochemistry, medical,Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm.14.95

Reference90 articles.

1. Cancer statistics, 2013

2. Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors

3. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

4. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer;Scientific Reports;2022-06-03

2. Identification of a risk prediction model for clinical prognosis in HER2 positive breast cancer patients;Genomics;2021-11

3. Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer;Modern Pathology;2021-09-07

4. Deep learning trained on H&E tumor ROIs predicts HER2 status and Trastuzumab treatment response in HER2+ breast cancer;2021-06-15

5. Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance;Essays in Biochemistry;2018-08-02